▶ 調査レポート

診断用放射性医薬品および造影剤の世界市場:放射性医薬品別、造影剤別、地域別分析

• 英文タイトル:Global Diagnostic Radiopharmaceuticals & Contrast Media Market – Radiopharmaceuticals Segmented by Type of Imaging, Application, Contrast Media Segmented by Application, Procedure, indication, Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。診断用放射性医薬品および造影剤の世界市場:放射性医薬品別、造影剤別、地域別分析 / Global Diagnostic Radiopharmaceuticals & Contrast Media Market – Radiopharmaceuticals Segmented by Type of Imaging, Application, Contrast Media Segmented by Application, Procedure, indication, Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08156資料のイメージです。• レポートコード:B-MOR-08156
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、診断用放射性医薬品および造影剤の世界市場について調べ、診断用放射性医薬品および造影剤の世界規模、市場動向、市場環境、放射性医薬品別分析、造影剤別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・診断用放射性医薬品および造影剤の世界市場インサイト
・診断用放射性医薬品および造影剤の世界市場環境
・診断用放射性医薬品および造影剤の世界市場動向
・診断用放射性医薬品および造影剤の世界市場規模
・診断用放射性医薬品および造影剤の世界市場規模:放射性医薬品別
・診断用放射性医薬品および造影剤の世界市場規模:造影剤別
・診断用放射性医薬品および造影剤の世界市場:地域別市場規模・分析
・診断用放射性医薬品および造影剤の北米市場規模・予測
・診断用放射性医薬品および造影剤のアメリカ市場規模・予測
・診断用放射性医薬品および造影剤のヨーロッパ市場規模・予測
・診断用放射性医薬品および造影剤のアジア市場規模・予測
・診断用放射性医薬品および造影剤の日本市場規模・予測
・診断用放射性医薬品および造影剤の中国市場規模・予測
・診断用放射性医薬品および造影剤のインド市場規模・予測
・診断用放射性医薬品および造影剤の韓国市場規模・予測
・関連企業情報・競争状況

The global diagnostic radiopharmaceuticals & contrast media market is expected to register a CAGR of 9%, during the forecast period, 2018 to 2023. The contrast media plays an important role in enhancing the imaging facilities for better diagnosis. There are many technical innovations in the market that are expected to contribute to the growth of the market during the forecast period. There has been an increase in the volume of the procedures that are being carried out; the CT market by itself is growing at 6% annually.

High Prevalence of Cancer and Heart Diseases

Cancer and cardiovascular disease are the two most common causes of mortality. Increasing incidents of cancer and cardiac ailments are the major drivers for this market. Imaging agents show immense potential in treating cancer and heart diseases.
Cancer: Diagnosing with nuclear imaging techniques has been observed to have greater impact on patient management for the way of monitoring tumor and its response to drugs. The emerging radiotracer approaches possess enormous potential for tumor imaging. They are pivotal in cancer patient management, which is a key growth factor for this market
Heart Diseases: Cardiology applications will continue to demonstrate strong growth in the market. In cardiology, imaging with SPECT & PET radiopharmaceuticals plays an important role in the diagnosis as well as management of patients with coronary artery disease, atherosclerosis and other cardiovascular diseases. Several promising modalities and imaging agents are available for clinical cardiovascular molecular imaging. Signal detection compounds include radioisotopes for PET and SPECT imaging, paramagnetic (gadolinium)/superparamagnetic (iron oxide) agents for MRI, fluorochromes for near-infrared fluorescence imaging and micro bubbles for ultrasound imaging. Currently, SPECT imaging using Technetium-99m products is often an important component of evaluation of patients, with known or suspected coronary artery diseases. The prevalence of cardiovascular conditions is high across the world and is increasing.
As the prevalence of cancer and heart diseases are rising the market of diagnostic radiopharmaceuticals & contrast media market is also expected to grow. The other factors, such as technology advancements in medical imaging, and increasing demand for image guided procedures and diagnosis are driving the diagnostic radiopharmaceuticals & contrast media market.

Short Half Life of Radiopharmaceuticals

An obstacle for the growth of the radiopharmaceuticals market is the limited accessibility of radionuclides with short half-lives (i.e. less than 30 minutes). Although these radionuclides have many advantages, their short half-life states that imaging can be done near the area they are produced. Compounds labeled with radionuclides of shorter physical half-lives are not supplied to the distribution centers present beyond a 100-mile radius. Therefore, their use is confined to the institutions capable of onsite radionuclide production and radiotracer chemistry. The current supply is from a few cyclotrons that are primarily used to produce Fluorine -18. The problems and delays in the transportation of short-lived radioactive materials affect the end-use of the product. Therefore, the preparation of radiopharmaceuticals is usually carried out in the hospital radio-pharmacy shortly before administration to the patient (Ex: PET radionuclides carbon-11, nitrogen-13, oxygen-15, etc.). So, this short life of radiopharmaceuticals are hindering the growth of diagnostic radiopharmaceuticals & contrast media market. The other factors, such as expensive procedures & regulatory complications are also hindering the growth of the market.

US Lead the Market in North America Region

The US diagnostic radiopharmaceuticals & contrast media market holds the largest market share in 2017 in North America region due to the presence of high quality healthcare system and modern medical technology in the country. Additionally, the increasing prevalence of cardiac and cancer is likely to contribute towards the growth of the stem cell market.

Key Developments in the Market

• January 2018: Guerbet has acquired the Accurate Medical Therapeutics. The acquisition will fuel Guerbet’s growth in interventional radiology and strengthen its current portfolio
• March 2017: GE Healthcare expanded the MRI contrast media product range in Europe with macrocyclic agent Clariscan

Major Players: BAYER HEALTHCARE, GE HEALTHCARE GUERBET GROUP, BRACCO IMAGING S.P.A, MALLINCKRODT PLC, LANTHEUS HOLDINGS, INC., AMAG PHARMACEUTICALS, INC., MEDTRONIC, NORDION, INC. are among others.

Reasons to Purchase this Report

• Current and future global diagnostic radiopharmaceuticals & contrast media market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players
• 3-month analyst support along with the Market Estimate sheet in excel

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Technology Advancements in Medical Imaging
6.1.2 Increasing Demand for Image Guided Procedures and Diagnostics
6.1.3 High Prevalence of Cancers and Cardiac Diseases
6.2 Market Restraints
6.2.1 High Costs of the Techniques- Not Easily Affordable
6.2.2 Limited Health Insurance Coverage
6.2.3 Short Half-life of Radiopharmaceuticals
6.3 Market Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Radiopharmaceuticals
7.1.1 By Type of Imaging Modality
7.1.1.1 SPECT
7.1.1.1.1 Tc-99
7.1.1.1.2 Tl-201
7.1.1.1.3 Ga-67
7.1.1.1.4 I-123
7.1.1.1.5 Others
7.1.1.2 PET
7.1.1.2.1 F-18
7.1.1.2.2 Ru-82
7.1.1.2.3 Others
7.1.2 By Application
7.1.2.1 Diagnostic Application
7.1.2.1.1 SPECT Applications
7.1.2.1.1.1 Cardiology
7.1.2.1.1.2 Neurology
7.1.2.1.1.3 Thyroid
7.1.2.1.1.4 Others
7.1.2.1.2 PET Application
7.1.2.1.2.1 Oncology
7.1.2.1.2.2 Cardiology
7.1.2.1.2.3 Neurology
7.1.2.1.2.4 Others
7.1.2.2 Therapeutic Application
7.1.2.2.1 Thyroid
7.1.2.2.2 Lymphoma
7.1.2.2.3 Endocrine Tumors
7.1.2.2.4 Others
7.2 Contrast Media
7.2.1 By Application
7.2.1.1 Ionizing Radiation based Radioimaging
7.2.1.2 Non-Ionizing Radiation based Radioimaging
7.2.1.3 Others
7.2.2 By Procedure
7.2.2.1 X-ray/Computed Tomography (CT)
7.2.2.1.1 Iodinated Contrast Media Ionic
7.2.2.1.2 Iodinated Contrast Media Non-Ionic
7.2.2.1.3 Barium-Based Contrast Media
7.2.2.2 Magnetic Resonance Imaging (MRI)
7.2.2.2.1 Gadolinium-Based Contrast Media
7.2.2.2.2 Others
7.2.2.3 Ultrasound
7.2.3 By Indication
7.2.3.1 Cardiovascular Disease
7.2.3.2 Oncology
7.2.3.3 Gastrointestinal Disorders
7.2.3.4 Neurological Disorders
7.2.3.5 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Amag Pharmaceuticals, Inc.
9.2 Bayer Healthcare
9.3 Bracco Imaging S.p.A
9.4 Daiichi Sankyo Co., Ltd.
9.5 GE Healthcare
9.6 Guerbet Group
9.7 Lantheus Holdings, Inc.
9.8 Mallinckrodt PLC
9.9 Medtronic
9.10 Nordion, Inc.
List Not Exhaustive
10. Future of the Market